-$6.32
$27.47
bear -$6.32
base $9.35
bull $27.47
margin of safety $3.50
market price* $6.27
Business condition attached to the margin of safety
U.S. revenue flat or higher year over year for at least two consecutive quarters (excluding the Owen Mumford acquisition), gross margin at or above roughly 60%, and debt below about $1.3 billion.
embecta sells insulin syringes and pen needles for people with diabetes. It was spun out of Becton Dickinson in April 2022 and now runs as a stand-alone company with about $1.0-1.1 billion of annual revenue and gross margins that were 62.6% last fiscal year. Its three largest customers (the distributors Cencora, McKesson and Cardinal Health) are about 42% of sales. The business is highly cash generative but carries about $1.47 billion of debt, so the shares are a small slice of the value left after lenders. WHAT WE MEASURED. We look at the cash the business produces before paying its lenders, after stock compensation and after the capital spending needed to stay in business, with one-time working-capital swings taken out. Two large swings were removed: in fiscal 2024 receivables jumped $175 million when BD's receivable-factoring arrangements ended and embecta had to collect its own customers' bills, and in fiscal 2025 embecta sold $63 million of receivables to a bank. Neither is earning power. On this basis the business produced $5.33 per share in fiscal 2022, $3.65 in 2023, $2.73 in 2024 and $4.72 in 2025 (before about $0.45 per share of cash interest tax shield effects; interest itself was $104 million in 2025). Fiscal 2020 and 2021 were carve-out years inside BD and are not comparable. We anchor on the median of fiscal 2023-2025, the three stand-alone years: $3.65 per share, about $215 million a year. Those years carried separation and stand-up costs of roughly $99 million, $111 million and $31 million, which are now mostly finished; that helps, but it is roughly offset by weaker recent trading (see below), and nine-month fiscal 2026 results, annualised, land close to the same $3.6 per share, so the level holds. WHAT IS HAPPENING. Revenue has fallen from $1,165 million in fiscal 2021 to $1,080 million in fiscal 2025 (down 3.8% last year), and the slide accelerated in fiscal 2026: revenue for the nine months to June 2026 was $755 million, down 7.6%, with $60 million lost to volume and $27 million to price. In the June quarter U.S. revenue fell 24.6% to $121 million (management points to customer and payer mix hurting net price, falling insulin pen prescriptions and the spread of GLP-1 drugs), while international revenue grew 11.5% to $151 million. Gross margin fell to 56.4% from 66.7%. The dividend was cut from $0.15 to $0.01 a quarter and the company is prioritising debt repayment; it repaid about $128 million of debt in the first nine months. In May 2026 embecta bought Owen Mumford, a UK maker of injection devices, for about GBP 100 million up front plus up to GBP 50 million of earn-out tied to its Aidaptus auto-injector, funded with a $180 million draw on the revolving credit line. Owen Mumford earned essentially nothing last year ($1.1 million of operating income on $92 million of revenue), so we credit it with no earnings while counting what it cost. We do not credit the patch-pump program (discontinued in 2025 and its assets being sold) or any recovery in U.S. pricing. GROWTH CHECK. Actual growth in the business cash flow per share in fiscal 2025 was +73% (owner earnings per share $2.96 versus $0.71), but that was the roll-off of one-time separation costs and a distorted 2024, not growth in the franchise. Year one of our base case assumes a 6% decline, below the trailing figure, because revenue is falling faster than that. WHAT EACH CASE ASSUMES.
Base: cash flow starts at $3.65 per share and declines 6% a year for five years (pen needle and syringe volumes have fallen each year since 2021 and the June-quarter U.S. decline shows no sign of ending; international growth cushions it), then 4% a year thereafter, reflecting a customer base of insulin-dependent patients that persists but shrinks. The business is worth about $32.1 per share. Debt and other obligations come to about $22.8 per share: $1,469 million of borrowings, a $38 million earn-out liability, less about $165 million of cash beyond operating needs. Result: about $9.35 per share.
Bear: the June-quarter U.S. pace of decline persists. Cash flow falls 15% a year for three years and 8% a year afterwards. The Term Loan (about $639 million, due March 2029) and $700 million of secured notes (due February 2030) then have to be refinanced from a shrinking, B1/B+ rated business, at roughly 4 percentage points more than today, and the amended credit agreement (August 2026) already carries tighter covenants; the leverage covenant limit is 4.75x against about 3.7x now on the company's definition. The business is worth about $19.5 per share, debt and obligations $22.8, and the extra cost of refinancing about $3.1, so the company appears to owe more than it is worth: about $6.3 per share, or roughly $370 million. That means shareholders would be left with nothing.
Bull: the identified cost levers work. Separation costs finish rolling off (worth roughly $0.45 per share a year against our anchor) and the decline slows to 2% a year, in line with the 1.9% average annual revenue decline of 2021-2025, with international growth offsetting some U.S. erosion. The business is worth about $50.2 per share against $22.8 of net obligations, or about $27.5. Growth was credited in no case, because nothing in the filings puts growth in the bag; international expansion, Owen Mumford's Aidaptus auto-injector and any U.S. price recovery are left out for lack of evidence of earnings. WHAT COULD MAKE THIS ESTIMATE WRONG. Debt is the swing factor: with equity only about a quarter of the business's value in the base case, a 10% error in the cash-flow level moves the per-share value by about 35%. Upside surprises would come from the U.S. decline stabilising or from Owen Mumford turning profitable faster than its history suggests. Downside: the U.S. decline seen in the June 2026 quarter proves a step change in price rather than a one-off, or lenders tighten before the 2027 revolver tranche and 2029-2030 maturities. We could not reconcile the full breakdown of the June 2026 debt balance to a filing, since the quarterly report text was not available to us; we used reported balance-sheet totals and the company's earnings materials.